15-Lipoxygenase inhibitors as anti-atherosclerotic agents

IDrugs

Volumn 1, Issue 2, 1998, Pages 206-213

  Cornicelli, Joseph A ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33747461436     PISSN: 13697056     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (70)

1. Ross R: Atherosclerosis: Current understanding of mechanisms and future strategies in therapy. Transplant Proc (1993) 25:2041-3.
2. Ross R, Agius L: The process of atherogenesis - Cellular and molecular interaction: From experimental animal models to humans. Diabetologia (1992) 35 (Suppl 2):S34-40.
3. Ross R: The pathogenesis of atherosclerosis: A perspective for the 1990s. Nature (1993) 362:801-9.
4. Williams KJ, Tabas I: The response-to-retention hypothesis of early atherogenesis. Arterioscler Thromb Vasc Biol (1995) 15:551-61.
5. Suckling KE: Emerging strategies for the treatment of atherosclerosis as seen from the patent literature. Biochem Soc Trans (1993) 21:660-2.
6. Stemme S, Hansson GK: Immune mechanisms in atherosclerosis. Coronary Artery Dis (1994) 5:216-22.
7. Brown MS, Goldstein JL: Lipoprotein metabolism in the macrophage: Implications for cholesterol deposition in atherosclerosis. Annu Rev Biochem (1983) 52:223-61.
8. Daugherty A: Lipoprotein receptors in arterial tissue: Relation to the pathology of atherosclerosis. Coronary Artery Dis (1994) 5:211-5.
9. Auerbach BJ, Bisgaier CL, Wölle J, Saxena U: Oxidation of low density lipoproteins greatly enhances their asso-ciation with lipoprotein lipase anchored to endothelial cell matrix. J Biol Chem (1996) 271:1329-35.
10. Haberland ME, Fong D, Cheng L: Malondialdehyde-altered protein occurs in atheroma of Watanabe Heritable Hyperlipidemic rabbits. Science (1988) 241:215-8.
11. Ylä-Herttuala S, Rosenfeld ME, Parthasarathy S, Glass CK, Sigal E, Witztum JL, Steinberg D: Colocalization of 15-lipoxygenase mRNA and protein with epitopes of oxidized low density lipoprotein in macrophage-rich areas of atherosclerotic lesions. Proc Natl Acad Sci USA (1990) 87:6959-63.
12. Ylä-Herttuala S, Rosenfeld ME, Parthasarathy S, Sigal E, Sarkioja T, Witztum JL, Steinberg D: Gene expression in macrophage-rich human atherosclerotic lesions. 15-lipoxygenase and acetyl low density lipoprotein receptor messenger RNA colocalize with oxidation specific lipid protein adducts. J Clin Invest (1991) 87:1146-52.
13. Daugherty A, Zweifel BS, Sobel BE, Schonfeld G: Isolation of low density lipoprotein from athero-sclerotic vascular tissue of Watanabe heritable hyperlipidemic rabbits. Arteriosclerosis (1988) 8:768-77
14. Ylä-Herttuala S, Palinski W, Rosenfeld ME, Parthasarathy S, Carew TE, Butler S, Witztum JL, Steinberg D: Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man. J Clin Invest (1989) 84:1086-95.
15. Yamamoto S: Mammalian lipoxygenases: Molecular structures and functions. Biochim Biophys Acta Lipids Lipid Metab (1992) 1128:117-31.
16. Ford-Hutchinson AW: Arachidonate 15-lipoxygenase; Characteristics and potential biological significance. Eicosanoids (1991) 4:65-74.
17. Kühn H, Belkner J, Wiesner R, Brash AR: Oxygenation of biological membranes by the pure reticulocyte lipoxygenase. J Biol Chem (1990) 265:18351-61.
18. Belkner J, Wiesner R, Rathman J, Bamett J, Sigal E, Kühn H: Oxygenation of lipoproteins by mammalian lipoxy-genases. Eur J Biochem (1993) 213:251-61.
19. Belkner J, Wiesner R, Kühn H, Lankin VZ: The oxygenation of cholesterol esters by the reticulocyte lipoxygenase. FEBS Lett (1991) 279:110-4.
20. Kühn H, Belkner J, Suzuki H, Yamamoto S: Oxidative modification of human lipoproteins by lipoxygenases of different positional specificities. J Lipid Res (1994) 35:1749-59.
21. Bolgar MS, Yang CY, Gaskell SJ: First direct evidence for lipid/protein conjugation in oxidized human low density lipoprotein. J Biol Chem (1996) 271:27999-8001.
22. Esterbauer H, Dieber-Rotheneder M, Waeg G, Striegl G, Jürgens G: Biochemical, structural, and functional properties of oxidized low-density lipoprotein. Chem Res Toxicol (1990) 3:77-92.
23. Esterbauer H, Jürgens G, Quehenberger O, Koller E: Autoxidation of human low density lipoprotein: loss of polyunsaturated fatty acids and vitamin E and generation of aldehydes. J Lipid Res (1987) 28:495-509.
24. Parthasarathy S, Wieland E, Steinberg D: A role for endothelial cell lipoxygenase in the oxidative modification of low density lipoprotein. Proc Natl Acad Sci USA (1991) 86:1046-50.
25. Sparrow CP, Olszewski J: Cellular oxidative modification of low density lipoprotein does not require lipoxygenases. Proc Natl Acad Sci USA (1992) 89:128-31.
26. Jessup W, Dartey-Usmar V. O'Leary V, Bedwell S: 5-Lipoxygenase is not essential in macrophage-mediated oxidation of low-density lipoprotein. Biochem J (1991) 278:163-9.
27. Sun DX, Funk CD: Disruption of 12/15-lipoxygenase expression in peritoneal macrophages - Enhanced utilization of the 5-lipoxygenase pathway and diminished oxidation of low density lipoprotein. J Biol Chem (1996) 271:24055-62.
28. Chen XS, Kurre U, Jenkins NA, Copeland NG, Funk CD: cDNA cloning, expression, mutagenesis of C-terminal isoleucine, genomic structure, and chromosomal localizations of murine 12-lipoxygenases. J Biol Chem (1994) 269:13979-87.
29. Benz DJ, Mol M, Ezaki M, Mori-Ito N, Zelan I, Miyanohara A, Friedmann T, Parthasarathy S, Steinberg D, Witztum JL: Enhanced levels of lipoperoxides in low density lipoprotein Incubated with murine fibroblasts expressing high levels of human 15-lipoxygenase. J Biol Chem (1995) 270:5191-7.
30. Ezaki M, Witztum JL, Steinberg D: Lipoperoxides in LDL incubated with fibroblasts that overexpress 15-lipoxygenase. J Lipid Res (1995) 36:1996-2004.
31. Scheidegger KJ, Butler S, Witztum JL: Angiotensin II increases macrophage-mediated modification of low density lipoprotein via a lipoxygenase-dependent pathway. J Biol Chem (1997) 272:21609-15.
32. Nadel JA, Conrad DJ, Ueki IF, Schuster A, Sigal E: immunocytochemical localization of arachidonate 15-lipoxygenase in erythrocytes, leukocytes, and airway cells. J Clin Invest (1991) 87:1139-45.
33. Hiltunen T, Luoma J, Nikkari T, Ylä-Herttuala S: Induction of 15-lipoxygenase mRNA and protein in early atherosclerotic lesions. Circulation (1995) 92:3297-303.
34. Sendobry SM, Comicelli JA, Welch K, Bocan T, Tait B, Trivedi BK, Colbry N, Dyer RD, Feinmark SJ, Daugherty A: Attenuation of diet-induced atherosclerosis in rabbits with a highly selective 15-lipoxygenase inhibitor lacking significant antioxidant properties. Br J Pharmacol (1997) 120:1199-206.
35. Henriksson P, Hamberg M, Diczfalusy U: Formation of 15-HETE as a major hydroxyeicosatetraenoic acid in the atherosclerotic vessel wall. Biochimica Biophysica Acta (1985) 834:271-4.
36. Simon TC, Makheja AN, Bailey JM: Formation of 15-hydroxyeicosatetraenoic acid (15-HETE) as the predominant eicosanoid in aortas from Watanabe Heritable Hyperlipidemic and cholesterol-fed rabbits. Atherosclerosis (1989) 75:31-8.
37. Bailey JM, Makheja AN, Lee R, Simon TH: Systemic activation of 15-lipoxygenase in heart, lung, and vascular tissues by hypercholesterolemia: Relationship to lipoprotein oxidation and atherogenesis. Athero-sclerosis (1995) 113:247-58.
38. Ylä-Herttuala S, Luoma J, Viita H, Hiltunen T, Sisto T, Nikkari T: Transfer of 15-lipoxygenase gene into rabbit iliac arteries results in the appearance of oxidation-specific lipid-protein adducts characteristic of oxidized low density lipoprotein. J Clin Invest (1995) 95:2692-8.
39. Harats D, Kurihara H, Belloni P, Oakley H, Ziober A, Ackley D, Cain G, Kurihara Y, Lawn R, Sigal E: Targeting gene expression to the vascular wall in transgenic mice using the murine preproendothelin-1 promoter. J Clin Invest (1995) 95:1335-44.
40. Harats D, Kurihara H, Levkovitz H, Sigal E: 15-lipoxygenase over-expression induces atherosclerosis in LDL receptor deficient mice. Proc Eur Atheroscler Soc (1996) 66:26.
41. Shen JH, Herderick E, Comhill JF, Zsigmond E, Kim HS, Kühn H, Guevara NV, Chan L: Macrophage-mediated 15-lipoxygenase expression protects against athero-sclerosis development. J Clin Invest (1996) 98:2201-8.
42. Shen JH, Kühn H, Petho-Schramm A, Chan L: Transgenic rabbits with the integrated human 15-lipoxygenase gene driven by a lysozyme promoter: Macrophage-specific expression and variable positional specificity of the transgenic enzyme. FASEB J (1995) 9:1623-31.
43. Kühn H, Belkner J, Zaiss S, Fahrenklemper T, Wohlfeil S: Involvement of 15-lipoxygenase in early stages of atherogenesis. J Exp Med (1994) 179:1903-11.
44. Kühn H, Heydeck D, Hugou I, Gniwotta C: In vivo action of 15-lipoxygenase in early stages of human atherogenesis. J Clin Invest (1997) 99:888-93.
45. Folcik VA, Nivar-Aristy RA, Krajewski LP, Cathcart MK: Lipoxygenase contributes to the oxidation of lipids in human atherosclerotic plaques. J Clin Invest (1995) 96:504-10.
46. 2+-catalysed oxidation. Biochem J (1996) 314:577-85.
47. Schnurr K, Belkner J, Ursini F, Schewe T, Kühn H: The selenoenzyme phospholipid hydroperoxide glutathione peroxidase controls the activity of the 15-lipoxygenase with complex substrates and preserves the specificity of the oxygenation products. J Biol Chem (1996) 271:4653-8.
48. Upston JM, Neuzil J, Witting PK, Alleva R, Stocker R: Oxidation of free fatty acids in low density lipoprotein by 15-lipoxygenase stimulates nonenzymic, ̈-tocopherol-mediated peroxidation of cholesteryl esters. J Biol Chem (1997) 272:30067-74.
49. Samuelsson B, Dahlen S-E, Lindgren JA, Rouzer CA, Serhan CN: Leukotrienes and lipoxins: Structures, biosynthesis, and biological effects. Science (1987) 237:1171-6.
50. Glasgow WC, Afshari CA, Barrett JC, Eling TE: Modulation of epidermal growth factor mitogenic response by metabolites of linoleic and arachidonic acid in Syrian hamster embryo fibroblasts. Differential effects in tumor suppressor gene (+) and (-) phenotypes. J Biol Chem (1992) 267:10771-9.
51. Glasgow WC, Hui R, Everhart AL, Jayawickreme SP, Angenman-Stewart J, Han B-B, Eling TE: The linoleic acid metabolite, (13S)-hydroperoxyoctadecadienoic acid, augments the epidermal growth factor receptor signaling pathway by attenuation of receptor dephosphorylatlon. J Biol Chem (1997) 272:19269-76.
52. Rao GN, Alexander RW, Runge MS: Unoleic acid and its metabolites, hydroperoxyoctadecadienoic acids, stimulate c-fos, c-jun, and c-myc mRNA expression, mitogen-activated protein kinase activation, and growth in rat aortic smooth muscle cells. J Clin Invest (1995) 96:842-7.
53. 2 in norepinephrine-induced arachidonic acid release in rabbit aortic smooth muscle cells. J Biol Chem (1996) 271:30149-57.
54. 2+/calmodulin-dependent protein kinase II by arachidonic acid and its metabolites. Proc Natl Acad Sci USA (1989) 86:8550-4.
55. Stoll LL, Morland MR, Spector AA: 13-HODE increases intracellular calcium in vascular smooth muscle cells. Am J Physiol Cell Physiol (1994) 266:C990-6.
56. Cho Y, Ziboh VA: Expression of protein kinase C isozymes in guinea pig epidermis: Selective inhibition of PKC-β activity by 13-hydroxyoctadecadienoic acid-containing diacylglycerol. J Lipid Res (1994) 35:913-21.
57. Rajavashisth TB, Andalibi A, Territo MC, Berliner JA, Navab M, Fogelman AM, Lusis AJ: Induction of endothelial cell expression of granulocyte and macrophage colony-stimulating factors by modified low density lipoproteins. Nature (1990) 344:254-7.
58. Schwartz D, Andalibi A, Chaverri-Almada L, Berliner JA, Kirchgessner T, Fang ZT, Tekamp-Olson P, Lusis AJ, Gallegos C, Fogelman AM, Territo MC: Role of the GRO family of chemokines in monocyte adhesion to MM-LDL-stimulated endothelium. J Clin Invest (1994) 94:1968-73.
59. Cushing SD, Berliner JA, Valente AJ, Territo MC, Navab M, Parhami F, Gerrity R, Schwartz CJ, Fogelman AM: Minimally modified LDL induces monocyte chemotactic protein-1 in human endothelial and smooth muscle cells. Proc Natl Acad Sci USA (1990) 87:5134-8.
60. Lehr HA, Hubner D, Ner's disease. Arch Neurol (1997) 54:465-473.
61. Sigari F, Bamett J, Hörkkö S, Witztum JL, Reaven PD: Fibroblasts expressing 15-lipoxygenase generate a bioactive, minimally modified low density lipoprotein. Circulation (1996) 94:I-400.
62. Khan BV, Parthasarathy SS, Alexander RW, Medford RM: Modified low density lipoprotein and its constituents augment cytokine-activated vascular cell adhesion molecule-1 gene expression in human vascular endothelial cells. J Clin Invest (1995) 95:1262-70.
63. Wölle J, Welch KA, Devall LJ, Cornicelli JA, Saxena U: Transient overexpression of human 15-lipoxygenase in aortic endothelial cells enhances tumor necrosis factor-induced vascular cell adhesion molecule-1 gene expression. Biochem Biophys Res Commun (1996) 220:310-4.
64. Gleason MM, Rojas CJ, Learn KS, Perrone MH, Bilder GE: Characterization and inhibition of 15-lipoxygenase in human monocytes: Comparison with soybean 15-lipoxygenase. Am J Physiol Cell Physiol (1995) 268:01301-7.
65. Tait BD, Dyer RD, Auerbach BJ, Bomemeier D, Guilds-Zamarka L, Oxender M, Roth BD, Trivedi BK, Cornicelli JA: Catecholbased inhibitors of 15-lipoxygenase. Bioorg Med Chem Lett (1996) 6:93-6.
66. Cho H, Ueda M, Tamaoka M, Hamaguchi M, Aisaka K, Kiso Y, Inoue T, Ogino R, Tatsuoka T, Ishihara T, Noguchi T, Morita I, Murota S: Novel caffeic acid derivatives: Extremely potent inhibitors of 12-lipoxygenase. J Med Chem (1991) 34:1503-5.
67. Gorins G, Kuhnert L, Johnson CR, Mamett U: (Carboxyalkyl) benzyl propargyl ethers as selective inhibitors of leukocytetype 12-lipoxygenases. J Med Chem (1996) 39:4871-8.
68. Funk CD: Molecular biology in the eicosanold field. Prog Nucl Acid Res (1993) 45:67-98.
69. Pryor WA, Cornicelli JA, Devall LJ, Tait B, Trivedi BK, Witiak DT, Wu M: A rapid screening test to determine the antioxidant potencies of natural and synthetic antioxidants. J Org Chem (1993) 58:3521-32.
70. Bocan TMA, Rosebury WS, Bak Mueller S, Lee P, Kuchera S, Welch K, Cornicelli JA: Antiatherosclerotic potential of PD 146176, a specific 15-lipoxygenase inhibitor, in diet-and chronic injury-induced rabbit models of atherosclerotic lesion progression and regression. Atherosclerosis (1998) (In Press).